Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief ...

Today, Benzinga's options scanner spotted 13 options trades for Amgen. This is not a typical pattern. The sentiment among ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Amgen is cruising through Wall Street like it just hit cruise control, earning a consensus "Hold" rating from 24 analysts.

Amgen Inc. company and executive profile by Barron's. View the latest AMGN company infomation and executive bios.

Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Vantage Wealth bulked up its portfolio by increasing its stake in Amgen by 4.2%, now holding over $21.6 million in shares.